1. Home
  2. ILLR vs ALDX Comparison

ILLR vs ALDX Comparison

Compare ILLR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ILLR
  • ALDX
  • Stock Information
  • Founded
  • ILLR 2015
  • ALDX 2004
  • Country
  • ILLR United States
  • ALDX United States
  • Employees
  • ILLR N/A
  • ALDX N/A
  • Industry
  • ILLR Investment Managers
  • ALDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ILLR Finance
  • ALDX Health Care
  • Exchange
  • ILLR Nasdaq
  • ALDX Nasdaq
  • Market Cap
  • ILLR N/A
  • ALDX 133.7M
  • IPO Year
  • ILLR N/A
  • ALDX 2014
  • Fundamental
  • Price
  • ILLR $1.00
  • ALDX $2.16
  • Analyst Decision
  • ILLR
  • ALDX Strong Buy
  • Analyst Count
  • ILLR 0
  • ALDX 2
  • Target Price
  • ILLR N/A
  • ALDX $9.50
  • AVG Volume (30 Days)
  • ILLR 635.3K
  • ALDX 1.5M
  • Earning Date
  • ILLR 05-20-2025
  • ALDX 05-20-2025
  • Dividend Yield
  • ILLR N/A
  • ALDX N/A
  • EPS Growth
  • ILLR N/A
  • ALDX N/A
  • EPS
  • ILLR N/A
  • ALDX N/A
  • Revenue
  • ILLR $45,244,000.00
  • ALDX N/A
  • Revenue This Year
  • ILLR N/A
  • ALDX N/A
  • Revenue Next Year
  • ILLR N/A
  • ALDX N/A
  • P/E Ratio
  • ILLR N/A
  • ALDX N/A
  • Revenue Growth
  • ILLR N/A
  • ALDX N/A
  • 52 Week Low
  • ILLR $0.51
  • ALDX $1.14
  • 52 Week High
  • ILLR $8.26
  • ALDX $7.20
  • Technical
  • Relative Strength Index (RSI)
  • ILLR N/A
  • ALDX 34.82
  • Support Level
  • ILLR N/A
  • ALDX $1.90
  • Resistance Level
  • ILLR N/A
  • ALDX $2.89
  • Average True Range (ATR)
  • ILLR 0.00
  • ALDX 0.23
  • MACD
  • ILLR 0.00
  • ALDX 0.10
  • Stochastic Oscillator
  • ILLR 0.00
  • ALDX 26.26

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: